Prediction of drug sensitivity and resistance of cancer by protein expression profiling

Cancer Genomics and Proteomics

Volumn 1, Issue 2, 2004, Pages 157-166

  Volm, Manfred ^a   Koomagi, Reet ^b   Efferth, Thomas ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Drug resistance; Drug sensitivity; Protein expression profiling

Indexed keywords

EID: 21344471922     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Rhoads CP: Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease. Trans Assoc Am Physicians 60: 110-117, 1947.
2. Salmon SE, Hamburger AW, Soehnlein B, Durie BG, Alberts DS and Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. New Engl J Med 298: 1321-1327, 1978.
3. Volm M, Kaufmann M, Hinderer H and Goerttler K: Rapid method for sensitivity testing of tumors against cytostatic agents. Klin Wschr 48: 374-376, 1970.
4. Volm M, Wayss K, Kaufmann M and Mattern J: Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15: 983-993, 1979.
5. Group for Sensitivity Testing of Tumors (KSST): In vitro short term test to determine the resistance of human tumors to chemotherapy. Cancer 48: 2127-2135, 1981.
6. Volm M, Mattern J and Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein and glutathion S-transferase in human lung tumors. Cancer 70: 764-769, 1992.
7. Beck WT, Grogan TM, Willmann CL, Cordon-Cardo C, Parham DM et al: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020, 1996.
8. Beck WT and Grogan TM: Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 11: 1107-1109, 1997.
9. Efferth T: Testing for tumor drug resistance in the age of molecular medicine. A contribution to the debate roundtable on phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice. Leukemia 13: 1627-1629, 1997.
10. Volm M and Mattern J: Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncogenesis 7: 227-244; 1996.
11. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L et al: A gene expression database for the molecular pharmacology of cancer. Nature Genetics 24: 236-244, 2000.
12. Huang JX, Mehrens D, Wiese R, Lee S, Tam SW et al: Highthroughput genomic and proteomic analysis using microarray technology. Clin Chem 47: 1912-1916, 2001.
13. Tyers M and Mann M: From genomics to proteomics. Nature 422: 193-197, 2003.
14. Bradley G, Juranka PF and Ling V: Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
15. Efferth T: The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1: 45-65,2001.
16. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2609, 1992.
17. Borst P, Kool M and Evers R: Do cMOAT (MRP2), other MRP homologues and LRP play a role in MDR? Sem Cancer Biol 8: 205-213, 1997.
18. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L et al: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer 65: 230-237, 1996.
19. Volm M and Mattern J: Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis 13: 1947-1950, 1992.
20. Volm M, Kästel M, Mattern J and Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinomas. Cancer 71: 3981-3987, 1993.
21. Cole SP, Chandra ER, Dicke FP, Gerlach JH and Mirski EL: Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345-3352, 1991.
22. Kaina B, Fritz G, Mitra S and Coquerelle T: transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: The role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12: 1857-1867, 1991.
23. Mattern J, Eichhorn U, Kaina B and Volm M: O6-methylguanine-DNA-methyl- transferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer 77: 919-922, 1998.
24. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegro CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
25. Stammler G, Sauerbrey A and Volm M: Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia. Cancer Lett 89: 129-135, 1995.
26. Whelan RDH, Hosking LK, Townsend AJ, Cowan KH and Hill BT: Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun 1: 359-365, 1989.
27. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
28. Schimke RT: Gene amplification in cultured cells. Cell 37: 705-713, 1984.
29. Huot J, Roy G, Lambert H, Chretien P and Landry J: Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 51: 245-252, 1991.
30. Scanlon KJ, Jiao L, Wang W, Tone T, Rossi JJ and Kashani-Sabet M: Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88: 10591-10595, 1991.
31. Volm M, Zintl F, Edler L and Sauerbrey A: Prognostic value of protein kinase C, proto-oncogene products and resistancerelated proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 28: 117-126, 1997.
32. Volm M, Zerban H, Mattern J and Efferth T: Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine. Carcinogenesis 11: 169-172, 1990.
33. Efferth T and Volm M: Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect Prevent 16: 237-243, 1992.
34. Efferth T and Grassmann R: Impact of viral oncogenesis on responses to anticancer drugs and irradiation. Crit Rev Oncogenesis 11: 165-187, 2000.
35. Volm M and Mattern J: Increased expression of Bcl-2 in drug resistant squamous cell lung carcinomas. Int J Oncol 7: 1333-1338, 1995.
36. Lowe SW, Ruley HE, Jacks T and Housman DE: p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
37. Volm M: P-glycoprotein associated expression of c-fos and cjun products in human lung carcinomas. Anticancer Res 13: 375-378, 1993.
38. Volm M, Sauerbrey A, Stammler G and Zintl F: Detection of Fos, Jun and Ras in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and PCR. Int J Oncol 4: 1251-1256, 1994.
39. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia (review). Am J Pathol 147: 545-560, 1995
40. Volm M, Brüggemann A, Günther M, Kleine W, Pfleiderer A and Vogt-Schaden M: Prognostic relevance of ploidy, proliferation and resistance-predictive tests in ovarian carcinoma. Cancer Res 45: 5180-5185, 1985.
41. Volm M, Koomägi R, Mattern J and Stammler G: Cyclin A is associated with an unfavourable outcome in patients with nonsmall cell lung carcinomas. Br J Cancer 75: 1774-1778, 1997.
42. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 6: 921-926, 1996.
43. Stammler G and Volm M: Apoptosis in non-small cell lung cancer as related to drug resistance and prognosis. Apoptosis 1: 95-99, 1996.
44. Koomägi R and Volm M: Expression of Fas (CD95/Apo-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer (Pred Oncol) 84: 239-243, 1999.
45. Giaccia AJ: Hypoxic stress proteins: Survival of the fittest. Sem Rad Oncol 6: 46-58, 1996.
46. Mattern L, Kallinowski F, Herfarth C and Volm M: Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 67: 20-23, 1996.
47. Koomägi R, Mattern J and Volm M: Up-regulation of resistance-related proteins in human lung tumors with poor vascularization. Carcinogenesis 16: 2129-2133, 1995.
48. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H and Tominaga T: Clincal significance of the determination of angiogenic factors. Eur J Cancer 32A: 2513-2519, 1996.
49. Volm M, Koomägi R, Mattern J and Stammler G: Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17: 99-104, 1997.
50. Volm M, Koomägi R and Mattern J. PD-ECGF, bFGF and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19: 651-656, 1999.
51. Koomägi R and Volm M: Tissue-factor expression in human nonsmall cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis. Int J Cancer (Pred Oncol) 79: 19-22, 1998.
52. Tanneberger S and Bacigalupo G: Experiences with individual cytostatic therapy of malignant tumors following pretherapeutic sensitivity test to cytostatics in vitro (oncobiogram). Arch Geschwulstforsch 35: 44-53, 1970.
53. Volm M, Bastert G, Mattern J and Wayss K: Oncobiogram and therapy success in transplantation neoplasms. Naturwissenschaften 60: 395, 1973.
54. Hurley JD and Yount LJ: Selection of anticancer drugs for palliation using tissue culture sensitivity studies. Am J Surg 109: 39-42, 1965.
55. Tanneberger S and Mohr A: Biological characterization of human tumours by means of organ culture and individualized cytostatic cancer treatment. Arch Geschwulstforsch 42: 307-315, 1973.
56. Sanfilippo O, Daidone MG, Costa A, Canetta R and Silvestrini R: Estimation of differential in vitro sensitivity of Non-Hodgkin's lymphomas to anticancer drugs. Eur J Cancer 17: 217-226, 1981.
57. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D and Makuch R: Association between human tumor colony-forming assay results and response of an individual patient's tumor chemotherapy. Am J Med 70: 1027-1032, 1981.
58. Giovanella BC, Stehlin JS, Williams LJ, Lee SS and Shepard RC: Heterotransplantation of human cancers into nude mice. Cancer 43: 2269-2281, 1978.
59. Mattern J, Bak M, Hahn EW and Volm M: Human tumor xenografts as model for drug testing. Cancer Metastas Rev 7: 263-284, 1988.
60. Mattern J and Volm M: Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev 267-298, 1982.
61. Volm M: Use of tritiated nucleotide incorporation for prediction of sensitivity of tumors to cytostatic agents. Behring Inst Mitt 74: 273-284, 1984.
62. Snijders AM, Meijer CA, Brachenhoff RH, van den Brule AJC and van Diest PJ: Microarray techniques in pathology: tool or toy? Clin Pathol Mol Pathol 53: 289-294, 2000.
63. Bittner M, Meltzer P, Chen Y , Jiang Y, Seftor E et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540, 2000.
64. Dhanasekaran SM, Barrette TR, Glosh D, Shah R, Varambally S et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
65. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U and Kaufmann M: Identification of high risk breast-cancer patients by gene expression profiling. The Lancet 359: 131-132, 2002.
66. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM et al: A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
67. Staunton JE, Slonin DK, Coller HA, Tamayo P, Angelo MJ et al: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sc USA 98: 10787-10792, 2001.
68. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H et al: An integrated database of chemosensitivity of 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147, 2002.
69. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T et al: Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527, 2002.
70. De Wildt RMT, Mundy CR, Gorick BD and Tomlinson IM: Antibody arrays for high-throughput screening of antibodyantigen interactions. Nature Biotech 18: 989-994, 2000.
71. MacBeath G and Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science 289: 1760-1763, 2000.
72. Kodadek T: Protein microarrays:prospects and problems. Chem Biol 8: 105-115, 2001.
73. Sreekumar A, Nyati MK, Varambally S, Barrette R, Ghosh D et al: Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins. Cancer Res 61: 7585-7593, 2001.
74. Huang RP: Detection of multiple proteins in a antibody-based protein microarray system. J Immun Meth 255: 1-13, 2001.
75. Cahill DJ: Protein and antibody arrays and their medical applications. J Immun Meth 250: 81-91, 2001.
76. Boguski MS and McIntosh MV: Biomedical informatics for proteomics. Nature 422: 233-237, 2003.
77. Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D and Lage H: Search of novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 20: 2952-2960, 1999.
78. Hütter S and Sinha P: Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 1: 1233-1248, 2001.
79. Poland J, Schadendorf D, Lage H, Schnölzer M, Celis JE and Sinha P: Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Med 40: 221-234, 2002.
80. Volm M and Rittgen W: Cellular predictive factors for the drug response of lung cancer. Anticancer Res 20: 3449-3458, 2000.
81. Volm M, Koomägi R, Mattern J and Efferth T: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87: 251-257, 2002.
82. Efferth T and Volm M: Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics & Proteomics 1: 17-22, 2004.
83. Volm M, Sauerbrey A, Zintl F, Koomügi R and Efferth T: Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses. Oncol Rep 9: 965-969, 2002.
84. Wooster R: Cancer classification with DNA microarrays. Is less more? Trends Genet 16: 327-329, 2000.
85. Kasten MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
86. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.